Serendipity

Serendipity Therapeutics is a clinical-stage biotechnology company based in Sweden that focuses on developing novel treatments for metabolic diseases, including obesity and type 2 diabetes. The company's primary approach involves the activation of brown adipose tissue (BAT) through highly selective beta-3 adrenergic receptor agonists. By stimulating brown fat, their lead candidates aim to increase energy expenditure and improve glucose homeostasis without the cardiovascular side effects typically associated with non-selective adrenergic stimulation. Their lead program, SND-11, has progressed into Phase 2 clinical trials, positioning the company as a key player in the next generation of metabolic health interventions.